ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model

Winardi, Daniel; Chu, Pei-Yi; Chen, Guan-Yu; Wang, Ke; Hsu, Wei-Yu; Hsieh, Ching-Liang; Chen, Yung-Hsiang; Wu, Yang-Chang*; Yang, Juan-Cheng*中国医科大学
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES2022-2DOI: 10.3390/ijms23031868
5被引3阅读
引用收藏
分享

摘要

Aurora A kinase (Aurora A) is a serine/threonine kinase regulating control of multiple events during cell-cycle progression. Playing roles in promoting proliferation and inhibiting cell death in cancer cells leads Aurora A to become a target for cancer therapy. It is overexpressed and associated with a poor prognosis in ovarian cancer. Improving cisplatin therapy outcomes remains an important issue for advanced-stage ovarian cancer treatment, and Aurora A inhibitors may improve it. In the present study, we identified natural compounds with higher docking scores than the known Aurora A ligand through structure-based virtual screening, including the natural compound fangchinoline, which has been associated with anticancer activities but not yet investigated in ovarian cancer. The binding and inhibition of Aurora A by fangchinoline were verified using cellular thermal shift and enzyme activity assays. Fangchinoline reduced viability and proliferation in ovarian cancer cell lines. Combination fangchinoline and cisplatin treatment enhanced cisplatin-DNA adduct levels, and the combination index revealed synergistic effects on cell viability. An in vivo study showed that fangchinoline significantly enhanced cisplatin therapeutic effects in OVCAR-3 ovarian cancer-bearing mice. Fangchinoline may inhibit tumor growth and enhance cisplatin therapy in ovarian cancer. This study reveals a novel Aurora A inhibitor, fangchinoline, as a potentially viable adjuvant for ovarian cancer therapy.

学科与关键词

关键词
Aurora A kinaseinhibitorfangchinolinecisplatinovarian cancermice
相关
加载中…
  • Natural anthraquinone compound emodin as a novel inhibitor of aurora A kinase: A pilot study
    Wu, Fen-Lan; Chu, Pei-Yi; Chen, Guan-Yu; Wang, Ke; Hsu, Wei-Yu; Ahmed, Azaj; Ma, Wen-Lung; Cheng, Wei-Chung; Wu, Yang-Chang*; Yang, Juan-Cheng*Chemical Biology and Drug Design, 2022, 99(1): 126-135.被引 7
  • Anlotinib induces apoptosis and second growth/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A/p53 pathway
    Wang, Hongli*; Wang, YuHuman and Experimental Toxicology, 2023, 42: 09603271231185774.被引 1
  • SARI 56497, an Exquisitely Selective Inhibitor of Aurora Kinases
    Carry, Jean-Christophe*; Clerc, Francois; Minoux, Herve; Schio, Laurent; Mauger, Jacques; Nair, Anil; Parmantier, Eric; Le Moigne, Ronan; Delorme, Cecile; Nicolas, Jean-Paul; Krick, Alain; Abecassis, Pierre-Yves; Crocq-Stuerga, Veronique; Pouzieux, Stephanie; Delarbre, Laure; Maignan, Sebastien; Bertrand, Thomas; Bjergarde, Kirsten; Ma, Nina; Lachaud, Sylvette; Guizani, Houlfa; Lebel, Remi; Doerflinger, Gilles; Monget, Sylvie; Perron, Sebastien; Gasse, FrancisJournal of Medicinal Chemistry, 2015, 58(1): 362-375.被引 27
查看全部 →

发表信息

论文状态
公开发表
期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
发表日期
2022-02
卷期
第 23 卷, 第 3 期
页码
1868
DOI
10.3390/ijms23031868
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
China Medical University [CMU110-MF-34, CMU108-MF-22]; Ministry of Science and Technology [MOST 107-2320-B-039 -017 -MY3, MOST 108-2320-B-039-062]

作者

  • W

    Winardi, Daniel (第一作者)

    china med univ

  • C

    Chu, Pei-Yi

    china med univ hosp

查看全部 9 位作者收起作者
  • C

    Chen, Guan-Yu

    china med univ hosp

  • W

    Wang, Ke

    china med univ hosp

  • H

    Hsu, Wei-Yu

    china med univ hosp

  • H

    Hsieh, Ching-Liang

    china med univ · china med univ hosp

  • C

    Chen, Yung-Hsiang

    china med univ

  • W

    Wu, Yang-Chang (通讯)

    china med univ hosp · china med univ

  • Y

    Yang, Juan-Cheng (通讯)

    china med univ hosp · china med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417